Trial Profile
A Phase Ia/Ib, Multicenter, Open-Label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination With Palbociclib and/or LHRH Agonist in Patients With Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Giredestrant (Primary) ; Gonadotropin releasing hormone; Palbociclib
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; First in man
- Sponsors Genentech
- 30 Jan 2023 Planned End Date changed from 15 Mar 2023 to 30 Jun 2025.
- 30 Jan 2023 Planned primary completion date changed from 15 Mar 2023 to 30 Jun 2025.
- 09 May 2022 Planned End Date changed from 30 Sep 2022 to 15 Mar 2023.